their pain. Their pain intensity during last episode of pain was 5 on a 10-point Numeric Rating Scale (NRS). 39% of the respondents had moderate pain (NRS = 5-7), 43% had severe pain (NRS = 7), 67% had headaches, 22% had back pain. 96% of the acute pain sufferers were using drugs for last three months. 96% of them were taking Aspirin® (acetyl salicilic acid), 91% Vermidon® (paracetamol), 90% Novalgin® (Dipyrone), and 80% Apranax® (naproxen sodium). CONCLUSION: Six percent of Turkish adults had acute pain. Sixty-seven percent of the respondents who had acute pain had accompying disease causing the pain. Pain is a major health care problem in Turkey that needs to be evaluated and researched in depth.
PAIN-Cost Studies PPN2 A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV INFUSION DICLOFENAC IN POST-OPERATIVE PAIN
Wallerstein KRB Pharma Focus, Belle Mead, NJ, USA OBJECTIVES: There are two forms of injectable IV diclofenac available (Dyloject bolus and Voltarol infusion). We conducted a cost minimization analysis to determine the total cost of each treatment strategy. METHODS: A decision-analytic model was developed to estimate total treatment costs of IV bolus versus IV infusion diclofenac. The modeled population was patients who post-operatively would require injectable NSAIDs to control their pain. The model timeframe was for the duration that a patient required post-operative pain management with injectable medication. The model inputs included the actual/estimated cost of medicines, the cost of the IV administration process (staff time and consumables), and the cost of treating adverse events (staff time, medicines and consumables). The unit costs and resources are based on UK data. The results are expressed as Pounds Sterling and as average cost per patient. One-way sensitivity analyses were also conducted on key parameters. RESULTS: The total cost of treating post-operative pain was less with IV bolus diclofenac (Dyloject) than with IV infusion diclofenac (Voltarol). Diclofenac IV bolus cost a mean Յ27.84 per patient overall versus diclofenac IV infusion mean cost of Յ78.61 per patient. The difference in overall cost is attributable to the cost of NSAIDs (IV bolus Յ12.19 versus Յ1.69 IV Infusion), the cost of administering the NSAID (IV bolus Յ9.72 versus Յ49.73 IV Infusion) and the cost of consumables (IV bolus Յ1.40 versus Յ16.72 IV infusion). The difference in the costs of rescue medication (IV bolus Յ2.48 versus Յ6.14 IV infusion) and of treating adverse events (IV bolus Յ2.061 versus Յ4.33 IV infusion) was less. One-way sensitivity analyses show the results are sensitive to the cost of staff time and consumables. CONCLUSION: Diclofenac IV bolus (Dyloject) is cost saving relative to diclofenac IV infusion (Voltarol) in the treatment of post-operative pain.
PPN3 EXPECTED COST AND COST CONSIDERATIONS ASSOCIATED WITH OPIOID ROTATION FOR CHRONIC NON-CANCER PAIN: A SIMULATION MODEL
Magar RS 1 , Fine PG 2 , White RE 3 1 PPD, Morrisville, NC, USA, 2 University of Utah-Pain Research Center, Salt Lake City, UT, USA, 3 Endo Pharmaceuticals, Chadds Ford, PA, USA OBJECTIVES: To develop an expected-cost model to examine the impact of opioid rotation among patients with chronic noncancer pain from the payor perspective METHODS: A decision tree was developed depicting pathways a patient may follow over the course of 1 year while taking long acting opioids. Up to 2 switches and 5 dose adjustments were possible for each of the three treatment arms: 1) MS Contin ER switch to OPANA ER; 2) MS Contin ER switch to OxyContin ER; and 3) OPANA ER switch to OxyContin ER for patients where morphine is not an appropriate first line treatment option. Cost data included drug acquisition costs for extended release (ER) and immediate release (IR) opioids, physician contact reimbursement for pain specialists and primary care physicians. Estimated rates for side effects were assumed similar for the most frequently reported side effects (constipation, nausea, somnolence and sedation) and were applied to all treatment arms. RESULTS: A total of 149 possible pathways of care were evaluated among the 3 treatment arms. Assuming a BID regimen, expected-cost range for treatments 1, 2, and 3 were: $3426-$4299, $3829-$5073, and $4556-$5098, respectively. IR cost contribution of the total expected-cost for treatment arms 1, 2, and 3 amounted to 17%, 21% and 24%, respectively, and was dependent on the total daily ER dose. CONCLUSION: Opioid rotation is thought to be the result of the need to switch opioids when a therapy is not well tolerated by the patient. Having an effective alternative for rotation/switching if first line treatment fails has the potential to reduce incremental down stream costs by decreasing physician contacts due to dose adjustment or the need for further switching. Furthermore, the lack of effective pain management combined with non-tolerated side effects may also require the need for additional medications for pain (IR) and side effects.
PPN4 HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN
Saldaña MT 1 , Navarro A 2 , Pérez C 3 , Torrades S 4 , Rejas J 5 1 Primary Care Centre "Raíces", Castrillón, Asturias, Spain, 2 Primary Care Centre "Puerta del Ángel", Madrid, Spain, 3 Hospital University La Princesa, Madrid, Spain, 4 European Biometric Institute, Barcelona, Spain, 5 Pfizer Spain, Madrid, Spain OBJECTIVES: To analyze health and non-health resources utilization and derived costs of treating treating refractory painful Radiculopathy followed in PCS under routine medical practice. METHODS: A 12-weeks cross-sectional and retrospective analysis was carried out in year 2006 in a whole-nation representative sample of PC centres. Men and women above 18 years, with chronic pain (6-month or more) due to cervical (17%) or lumbar (83%) radiculopathy, refractory to, at least, one previous analgesic were included in the analysis. Health resources included all-type medical visits, hospitalizations, complementary test and pharmacological and non-pharmacological therapies. Nonhealth included wages loses due to loss-work-days equivalents (LWDE = absenteeism days + days working with reduced productivity due to pain). Pain severity was measured by McGillpain scale. RESULTS: One-thousand-four-hundred-fifty-two subjects [55.8% women, 56.7 (12.5) years] with cervical or lumbar radiculopathy were analyzed. Last-week mean pain severity was 71.4 (15.1) mm with 61.4% declaring the pain as severe or worst the day of collecting data. Previous mean (SD) number of drugs was 2.6 (1.4), with a 24.0% on one-drug only; 81% on NSAIDs, 47% on paracetamol, 32% on opiods, 17% on muscle-relaxants, 9% on antiepileptics, and 7% on antidepressants. Quarterly mean LWDE was 41.1 (28.6) days. Medical visits average per trimester was 9.1 (6.2), with 3.9% declaring one-hospitalization. Quarterly total mean cost was €2970 (2114); €1032 (1207) direct health cost and €1938 (1490) indirect cost. CONCLUSION: In the primary care setting, health and non-health resources utilization under routine medical practice derived in substantial costs when treating refractory painful due to cervical or lumbar radiculopathy. About two-thirds of the total costs were derived from non-health resources.
PPN5 LONGITUDINAL HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS): A 12-WEEKS POST-HOC ANALYSIS OF THE PREGABALIN EFFECT UNDER ROUTINE MEDICAL PRACTICE
Pérez C 1 , Navarro A 2 , Saldaña MT 3 , Masramon X 4 , Rejas J 5 1 Hospital University La Princesa, Madrid, Spain, 2 Primary Care Centre "Puerta del Ángel", Madrid, Spain, 3 Primary Care Centre "Raíces", Castrillón, Asturias, Spain, 4 European Biometrics Institute, Barcelona, Spain, 5 Pfizer Spain, Madrid, Spain OBJECTIVES: To analyze the Pregabalin (PGB) effect under routine medical practice on longitudinal health and non-health resources utilization (HRU) and derived costs of treating refractory painful Radiculopathy in Primary Care Setting (PCS) during 12-weeks. METHODS: A representative sample of PC centres included men and women above 18 years, with chronic pain (6-month or more) due to cervical (17%) or lumbar (83%) radiculopathy refractory to, at least, one previous analgesic [mean (SD) number of drugs; 2.6 (1.4)], in a prospective, naturalistic, 12-weeks two-visit study. Health resources included all-type medical visits, hospitalizations, complementary test and pharmacological and non-pharmacological therapies. Non-health included wages loses due to loss-work-days equivalents (LWDE = absenteeism days + days working with reduced productivity due to pain). Pain severity was measured by McGill-pain scale. Descriptive statistics and ANCOVA models were applied to compare 12-weeks periods of treatment. RESULTS: Onethousand-three-hundred-fifty-one PGB-naive patients [55.8% women, 56.7 (12.5) years] were analyzed: 490 (36%) switched to PGB as monotherapy (PGBm), 702 (52%) patients received PGB as add-on therapy (PGBadd-on), and in 159 (12%) previous treatment was replaced by a regimen not including PGB (Non-PGB). As compared to non-PGB, both PGBm and PGBadd-on showed significantly higher HRU reduction. The extra costs of drugs, particularly in PGB subgroups [€15.4 (39.1), €148.6 (109.1) and €145.3 (119.6), respectively (p < 0.0001 within and between groups)] was off-set by higher significant reductions in all other components of health costs (except non-pharmacological therapies in non-PGB group) yielding to a greater total cost reductions: €1203.3 (1805.6), €1423.2 (1650.0) and €1429.2 (1966.2), respectively (p < 0.001 within and p = 0.0004 between groups). CONCLUSION: In the primary care setting either add-on or monotherapy with pregabalin under routine medical practice was associated with a significant longitudinal reduction in HRU and total costs when compared with non-PGB therapy in subjects with painful radiculopathy of cervical or lumbar origin.
PPN6 HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PERIPHERAL NEUROPATHIC PAIN (NEP) IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN
Navarro A 1 , Saldaña MT 2 , Pérez C 3 , Masramon X 4 , Rejas J 5 1 Primary Care Centre "Puerta del Ángel", Madrid, Spain, 2 Primary Care Centre "Raíces", Castrillón, Asturias, Spain, 3 Hospital University La Princesa, Madrid, Spain, 4 European Biometrics Institute, Barcelona, Barcelona, Spain, 5 Pfizer Spain, Madrid, Spain OBJECTIVES: To analyze health and non-health resources utilization and derived costs of treating patients with refractory peripheral NeP followed in PCS under routine medical practice. METHODS: A 12-weeks cross-sectional and retrospective analysis was carried out in year 2006 in a whole-nation representative sample of PC centres. Men and women above 18 years, with chronic pain (6-month or more) due to peripheral NeP (diabetic neuropathy, post-herpetic neuralgia or trigeminal neuralgia), and refractory to, at least, one previous analgesic were included in the analysis. Health resources included all-type medical visits, hospitalizations, complementary test and pharmacological and nonpharmacological therapies. Non-health included wages loses due to loss-work-days equivalents (LWDE = absenteeism days + days working with reduced productivity due to pain). Pain severity was measured by McGill-pain scale. RESULTS: One-thousandfour-hundred-thirty-nine subjects [58.8% women, 59.5 (12.7) years] were analyzed: 783 (54%) with diabetic painful neuropathy (DPN), 486 (34%) with post-herpetic neuralgia (PHN), and 170 (12%) with trigeminal neuralgia (TN). Last-week mean pain severity was 70.8 (16.1) mm with 60.2% declaring the pain as severe or worst the day of collecting data. Previous mean (SD) number of drugs was 2.3 (1.3), with a 30.3% on one-drug only; 72% on NSAIDs, 43% on paracetamol, 36% on opiods, 23% on antiepileptics, and 11% on antidepressants. Quarterly mean LWDE was 37.5 (27.6) days. Medical visits average per trimester was 9.7 (7.6), with 4.4% declaring one-hospitalization. Quarterly total mean cost was €2689 (2236); €983 (1394) direct health cost and €1706 (1440) indirect cost. Cost and health resources utilization were not associated to aetiological cause of pain. CONCLUSION: In the primary care setting, health and non-health resources utilization under routine medical practice derived in substantial costs when treating the associated refractory pain to peripheral neuropathies due to diabetes, postherpetic or trigeminal neuralgia. Two-thirds of the total costs were derived from non-health resources.
